Literature DB >> 23903552

Clinical significance and molecular characterization of nonsporulating molds isolated from the respiratory tracts of bronchopulmonary mycosis patients with special reference to basidiomycetes.

Pradeep Kumar Singh1, Shallu Kathuria, Kshitij Agarwal, Shailendra Nath Gaur, Jacques F Meis, Anuradha Chowdhary.   

Abstract

Nonsporulating molds (NSMs), especially basidiomycetes, have predominantly been reported as human pathogens responsible for allergic and invasive disease. Their conventional identification is problematic, as many isolates remain sterile in culture. Thus, inconclusive culture reports might adversely affect treatment decisions. The clinical significance of NSMs in pulmonary mycoses is poorly understood. We sequenced the internal transcribed spacer (ITS) region and D1/D2 domain of the larger subunit (LSU) of 52 NSMs isolated from respiratory specimens. The basidiomycetes were the predominant NSMs, of which Schizophyllum commune was the most common agent in allergic bronchopulmonary mycosis (ABPM), followed by Ceriporia lacerata in invasive fungal disease. Porostereum spadiceum, Phanaerochaete stereoides, Neosartorya fischeri, and Marasmiellus palmivorus were the other molds observed. Application of ITS and LSU region sequencing identified 92% of the isolates. The antifungal susceptibility data revealed that all basidiomycetes tested were susceptible to amphotericin B and resistant to caspofungin, fluconazole, and flucytosine. Except for 3 isolates of S. commune and a solitary isolate of M. palmivorus, all basidiomycetes had low MICs for itraconazole, posaconazole, and voriconazole. Basidiomycetes were isolated from patients with ABPM, invasive pulmonary mycosis/pneumonia, or fungal balls. In addition, the majority of the basidiomycetes were isolated from patients with chronic respiratory disorders who were sensitized to one of the basidiomycetous fungi and demonstrated precipitating antibodies against the incriminating fungi, indicating an indolent tissue reaction. Thus, isolation of basidiomycetes from the lower respiratory tract could be significant, and it is important to monitor these patients in order to prevent subsequent lung damage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23903552      PMCID: PMC3811655          DOI: 10.1128/JCM.01486-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi.

Authors:  G M González; D A Sutton; E Thompson; R Tijerina; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Pradeep Kumar Singh; Kshitij Agarwal; Shailendra N Gaur; Pradip Roy; Harbans S Randhawa; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

3.  Schizophyllum commune: an unusual isolate from a patient with allergic fungal sinusitis.

Authors:  S Clark; C K Campbell; A Sandison; D I Choa
Journal:  J Infect       Date:  1996-03       Impact factor: 6.072

Review 4.  Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview.

Authors:  Anuradha Chowdhary; Kshitij Agarwal; Shallu Kathuria; Shailendra Nath Gaur; Harbans Singh Randhawa; Jacques F Meis
Journal:  Crit Rev Microbiol       Date:  2013-02-05       Impact factor: 7.624

5.  Diagnostic difficulties caused by a nonclamped Schizophyllum commune isolate in a case of fungus ball of the lung.

Authors:  L Sigler; L M de la Maza; G Tan; K N Egger; R K Sherburne
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

Review 6.  Clinical use of immunoassays in assessing exposure to fungi and potential health effects related to fungal exposure.

Authors:  Douglas B Trout; James M Seltzer; Elena H Page; Raymond E Biagini; Detlef Schmechel; Daniel M Lewis; A Yvonne Boudreau
Journal:  Ann Allergy Asthma Immunol       Date:  2004-05       Impact factor: 6.347

7.  Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis.

Authors:  H Järv; J Lehtmaa; R C Summerbell; E S Hoekstra; R A Samson; P Naaber
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 8.  Brain abscess caused by Schizophyllum commune: an emerging basidiomycete pathogen.

Authors:  J D Rihs; A A Padhye; C B Good
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

9.  Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus Schizophyllum commune.

Authors:  K Kamei; H Unno; K Nagao; T Kuriyama; K Nishimura; M Miyaji
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

10.  Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil.

Authors:  Josep Guarro; Esper G Kallas; Patricio Godoy; Anna Karenina; Josepa Gené; Alberto Stchigel; Arnaldo Lopes Colombo
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

View more
  18 in total

1.  Reply to "implications of high antifungal susceptibility on Schizophyllum commune-associated allergy in clinical practice".

Authors:  Anuradha Chowdhary; Shallu Kathuria; Kshitij Agarwal; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2013-11       Impact factor: 5.191

Review 2.  Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.

Authors:  R Araujo; M Oliveira; A Amorim; B Sampaio-Maia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-18       Impact factor: 3.267

Review 3.  Aspergillus fumigatus and related species.

Authors:  Janyce A Sugui; Kyung J Kwon-Chung; Praveen R Juvvadi; Jean-Paul Latgé; William J Steinbach
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

4.  Schizophyllum radiatum, an Emerging Fungus from Human Respiratory Tract.

Authors:  J P Z Siqueira; D Sutton; J Gené; D García; M Guevara-Suarez; C Decock; N Wiederhold; J Guarro
Journal:  J Clin Microbiol       Date:  2016-07-20       Impact factor: 5.948

5.  Hypertrophic pachymeningitis caused by Schizophyllum sp.: a novel case report.

Authors:  Masaki Machida; Itaru Nakamura; Akihiro Sato; Shigeki Nakamura; Yoshitsugu Miyazaki; Hidehiro Watanabe
Journal:  Infection       Date:  2020-11-06       Impact factor: 3.553

6.  In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans.

Authors:  M Javad Najafzadeh; Deanna A Sutton; M Saradeghi Keisari; H Zarrinfar; G Sybren de Hoog; Anuradha Chowdhary; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

7.  Fatal empyema thoracis caused by Schizophyllum commune with cross-reactive cryptococcal antigenemia.

Authors:  Jasper F W Chan; Jade L L Teng; Iris W S Li; Sally C Y Wong; Sally S M Leung; Po-On Ho; Kelvin K W To; Susanna K P Lau; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

8.  A Case of Fungus Ball-Type Maxillary Sinusitis Due to Penicillium Roqueforti.

Authors:  T Radulesco; A Varoquaux; S Ranque; P Dessi; J Michel; C Cassagne
Journal:  Mycopathologia       Date:  2017-10-26       Impact factor: 2.574

9.  Determining the Pathogenic Potential of Non-sporulating Molds Isolated from Cutaneous Specimens.

Authors:  Nantha Kumar Jeyaprakasam; Mohd Fuat Abdul Razak; Noor Azimah Binti Ahmad; Jacinta Santhanam
Journal:  Mycopathologia       Date:  2016-02-03       Impact factor: 2.574

10.  Gloeostereum cimri, a novel shelf fungus isolated from a human pulmonary cyst.

Authors:  Sarah A Ahmed; Sybren de Hoog; Janet Kim; Jayne Crozier; Sarah E Thomas; Benjamin Stielow; David A Stevens
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.